氨磷汀治疗特发性血小板减少性紫癜高龄患者近期疗效观察

Early Effect of Amifostine in Treating Aged Patients with Idiopathic Thrombocytopenia Purpura

为了研究氨磷汀治疗特发性血小板减少性紫癜(ITP)的近期疗效,对3例用氨磷汀治疗的特发性血小板减少性紫癜的高龄患者进行了观察。患者的年龄分别为88、75和65岁。治疗方案为氨磷汀400毫克/天,每周连续5天静脉滴注后,休息2天,连用4周。结果表明:治疗4周以后3例患者均出现很好的近期疗效,2例患者血小板数在治疗开始后第1周恢复正常,1例在治疗2周后恢复正常,所有患者在治疗停止4个月后血小板数仍保持在正常水平,不需要激素、丙种球蛋白等其他治疗措施,且未见明显的毒副作用。结论:氨磷汀治疗高龄ITP患者具有良好的近期疗效,提示氨磷汀在ITP治疗方面有着良好的应用前景,但对其长期临床疗效有待进一步研究。

The purpose of this study was to explore the effect of amifostine in treating aged patients with idiopathic thrombocytopenic purpura （ITP） . Three aged ITP patients（ one aged 88, one aged 75, another aged 65 ）were treated with amifostine over a period of 4 weeks for each. The results showed that the early positive responses were observed in all 3 aged patients after treatment with amifostine 5 × 400 mg per week for 4 weeks, the recovery of platelet counts to normal level were found in 2 cases after 1 week and in 1 case after 2 weeks. Following 4 months after stop of treatment with amifostine, the normal platelet counts still remains in all patients, no more blood transfusions, hormonal preparation and γ-globulin were given. Amifostine has never been reported elewhere as to treat of aged ITP. In conclusion, amifostine has a good early therapeutic effect on aged ITP patients, but its clinical outcome of long-term still needs further evaluation.